CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • United States
    Entity • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade Annexon, Inc. - ANNX CFD

    2.61
    7.19%
    0.05
    Low: 2.49
    High: 2.84
    Market Trading Hours* (UTC) Open now
    Closes on Tuesday at 20:00

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.025457%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		0.003235%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 20%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Annexon Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.78
    Open* 2.84
    1-Year Change* -12.62%
    Day's Range* 2.49 - 2.84
    52 wk Range 2.07-7.65
    Average Volume (10 days) 2.25M
    Average Volume (3 months) 15.94M
    Market Cap 151.29M
    P/E Ratio -100.00K
    Shares Outstanding 53.08M
    Revenue N/A
    EPS -2.47
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Aug 7, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    May 26, 2023 2.78 0.71 34.30% 2.07 2.81 2.05
    May 25, 2023 2.06 -0.36 -14.88% 2.42 2.44 2.04
    May 24, 2023 5.15 -0.33 -6.02% 5.48 5.63 5.05
    May 23, 2023 5.57 -0.22 -3.80% 5.79 6.09 5.56
    May 22, 2023 5.94 0.27 4.76% 5.67 6.04 5.66
    May 19, 2023 5.86 0.13 2.27% 5.73 5.97 5.67
    May 18, 2023 5.76 -0.47 -7.54% 6.23 6.61 5.72
    May 17, 2023 6.35 0.38 6.37% 5.97 6.40 5.78
    May 16, 2023 6.00 0.06 1.01% 5.94 6.15 5.77
    May 15, 2023 6.03 0.60 11.05% 5.43 6.22 5.41
    May 12, 2023 5.44 -0.02 -0.37% 5.46 5.59 5.41
    May 11, 2023 5.45 -0.15 -2.68% 5.60 5.67 5.38
    May 10, 2023 5.59 0.20 3.71% 5.39 5.79 5.35
    May 9, 2023 5.43 0.33 6.47% 5.10 5.48 4.90
    May 8, 2023 5.21 0.17 3.37% 5.04 5.26 5.03
    May 5, 2023 5.24 0.14 2.75% 5.10 5.38 5.07
    May 4, 2023 5.17 0.23 4.66% 4.94 5.19 4.90
    May 3, 2023 5.06 0.36 7.66% 4.70 5.15 4.66
    May 2, 2023 4.85 -0.55 -10.19% 5.40 5.40 4.85
    May 1, 2023 5.43 0.18 3.43% 5.25 5.48 5.25

    Annexon, Inc. Events

    Time (UTC) Country Event
    Thursday, June 8, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Annexon Inc Annual Shareholders Meeting
    Annexon Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Friday, June 9, 2023

    Time (UTC)

    16:00

    Country

    US

    Event

    Annexon Inc Annual Shareholders Meeting
    Annexon Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Monday, August 7, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q2 2023 Annexon Inc Earnings Release
    Q2 2023 Annexon Inc Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, November 1, 2023

    Time (UTC)

    12:30

    Country

    US

    Event

    Q3 2023 Annexon Inc Earnings Release
    Q3 2023 Annexon Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 145.599 130.713 63.469 32.328 19.112
    Selling/General/Admin. Expenses, Total 33.098 30.647 14.198 7.994 3.619
    Research & Development 112.501 100.066 49.271 24.524 15.528
    Operating Income -145.599 -130.713 -63.469 -32.328 -19.112
    Other, Net 3.652 0.385 0.048 -4.865 0.769
    Net Income Before Taxes -141.947 -130.323 -63.412 -37.179 -18.303
    Net Income After Taxes -141.947 -130.323 -63.412 -37.183 -18.304
    Net Income Before Extra. Items -141.947 -130.323 -63.412 -37.183 -18.304
    Total Extraordinary Items
    Net Income -141.947 -130.323 -63.412 -37.183 -18.304
    Total Adjustments to Net Income 0 -6.924 -1.095 -0.176
    Income Available to Common Excl. Extra. Items -141.947 -130.323 -70.336 -38.278 -18.48
    Income Available to Common Incl. Extra. Items -141.947 -130.323 -70.336 -38.278 -18.48
    Diluted Net Income -141.947 -130.323 -70.336 -38.278 -18.48
    Diluted Weighted Average Shares 54.6736 38.3163 16.9624 187.289 187.289
    Diluted EPS Excluding Extraordinary Items -2.59626 -3.40124 -4.14658 -0.20438 -0.09867
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -2.59626 -3.40124 -4.14658 -0.20504 -0.09879
    Unusual Expense (Income) -0.19 -0.035
    Interest Income (Expense), Net Non-Operating 0.005 0.009 0.014 0.04
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 41.242 36.695 36.069 37.409 35.426
    Selling/General/Admin. Expenses, Total 8.897 8.16 8.207 8.303 8.428
    Research & Development 32.345 28.535 27.862 29.106 26.998
    Operating Income -41.242 -36.695 -36.069 -37.409 -35.426
    Other, Net 2.566 2.312 1.015 0.272 0.053
    Net Income Before Taxes -38.676 -34.383 -35.054 -37.137 -35.373
    Net Income After Taxes -38.676 -34.383 -35.054 -37.137 -35.373
    Net Income Before Extra. Items -38.676 -34.383 -35.054 -37.137 -35.373
    Net Income -38.676 -34.383 -35.054 -37.137 -35.373
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -38.676 -34.383 -35.054 -37.137 -35.373
    Income Available to Common Incl. Extra. Items -38.676 -34.383 -35.054 -37.137 -35.373
    Diluted Net Income -38.676 -34.383 -35.054 -37.137 -35.373
    Diluted Weighted Average Shares 73.8556 72.563 68.6529 38.5844 38.5634
    Diluted EPS Excluding Extraordinary Items -0.52367 -0.47384 -0.5106 -0.96249 -0.91727
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.52367 -0.47384 -0.5106 -0.96249 -0.91727
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 248.098 247.693 354.011 45.406 45.706
    Cash and Short Term Investments 242.657 242.715 351.206 43.931 44.175
    Cash & Equivalents 140.02 74.843 268.565 43.931 44.175
    Prepaid Expenses 5.238 4.515 2.802 1.396 1.306
    Total Assets 285.096 287.04 355.946 49.898 48.149
    Property/Plant/Equipment, Total - Net 35.966 38.181 1.935 2.138 2.345
    Property/Plant/Equipment, Total - Gross 38.849 38.97 3.906 3.442 3.156
    Accumulated Depreciation, Total -2.883 -0.789 -1.971 -1.304 -0.811
    Other Long Term Assets, Total 1.032 1.166 0 2.354 0.098
    Total Current Liabilities 22.36 21.744 10.622 4.931 3.326
    Accounts Payable 7.416 11.153 3.734 2.371 1.271
    Accrued Expenses 14.764 10.452 6.497 2.194 1.713
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.18 0.139 0.391 0.366 0.342
    Total Liabilities 53.902 55.131 11.668 6.368 5.129
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 31.542 33.387 1.046 1.437 1.803
    Total Equity 231.194 231.909 344.278 43.53 43.02
    Redeemable Preferred Stock 0 0 143.984 107.222
    Common Stock 0.048 0.039 0.038 0.004 0.004
    Additional Paid-In Capital 669.78 528.365 510.309 2.202 1.257
    Retained Earnings (Accumulated Deficit) -438.262 -296.315 -165.992 -102.58 -65.397
    Other Equity, Total -0.372 -0.18 -0.077 -0.08 -0.066
    Total Liabilities & Shareholders’ Equity 285.096 287.04 355.946 49.898 48.149
    Total Common Shares Outstanding 47.723 38.5608 38.1576 187.289 187.289
    Total Receivables, Net 0 0.003 0.079 0.225
    Short Term Investments 102.637 167.872 82.641
    Other Current Assets, Total 0.203 0.463
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 232.536 248.098 274.777 181.372 211.254
    Cash and Short Term Investments 228.165 242.657 269.519 177.594 206.659
    Cash & Equivalents 144.12 140.02 210.658 104.614 112.828
    Short Term Investments 84.045 102.637 58.861 72.98 93.831
    Total Receivables, Net
    Prepaid Expenses 4.206 5.238 5.201 3.741 4.461
    Total Assets 268.778 285.096 312.722 220.704 250.569
    Property/Plant/Equipment, Total - Net 35.198 35.966 36.709 37.282 37.908
    Accumulated Depreciation, Total -3.419 -2.883 -2.353 -1.834 -1.295
    Other Long Term Assets, Total 1.044 1.032 1.236 2.05 1.407
    Total Current Liabilities 22.941 22.36 20.22 20.254 17.053
    Accounts Payable 10.346 7.416 6.921 10.301 9.378
    Accrued Expenses 12.211 14.764 13.129 9.789 7.486
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.384 0.18 0.17 0.164 0.189
    Total Liabilities 53.917 53.902 52.12 52.66 49.955
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 30.976 31.542 31.9 32.406 32.902
    Total Equity 214.861 231.194 260.602 168.044 200.614
    Common Stock 0.053 0.048 0.048 0.039 0.039
    Additional Paid-In Capital 691.963 669.78 664.839 537.269 532.636
    Retained Earnings (Accumulated Deficit) -476.938 -438.262 -403.879 -368.825 -331.688
    Other Equity, Total -0.217 -0.372 -0.406 -0.439 -0.373
    Total Liabilities & Shareholders’ Equity 268.778 285.096 312.722 220.704 250.569
    Total Common Shares Outstanding 53.0807 47.723 47.6265 38.6039 38.5636
    Property/Plant/Equipment, Total - Gross 38.617 38.849 39.062 39.116 39.203
    Other Current Assets, Total 0.165 0.203 0.057 0.037 0.134
    Redeemable Preferred Stock
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -141.947 -130.323 -63.412 -37.183 -18.304
    Cash From Operating Activities -116.309 -106.11 -53.087 -28.358 -17.19
    Cash From Operating Activities 2.106 2.141 0.667 0.493 0.488
    Non-Cash Items 19.794 18.788 4.941 7.707 0.148
    Cash Taxes Paid 0 0.002 0.001
    Changes in Working Capital 3.738 3.284 4.717 0.625 0.478
    Cash From Investing Activities 58.443 -88.236 -83.164 -0.267 -0.017
    Capital Expenditures -6.526 -1.654 -0.464 -0.267 -0.017
    Cash From Financing Activities 122.908 1.795 360.876 28.395 58.456
    Issuance (Retirement) of Stock, Net 130.896 1.795 363.85 30 58.456
    Foreign Exchange Effects 0.001 -0.005 0.009 -0.014 -0.04
    Net Change in Cash 65.043 -192.556 224.634 -0.244 41.209
    Financing Cash Flow Items -7.988 0 -2.974 -1.605 0
    Other Investing Cash Flow Items, Total 64.969 -86.582 -82.7
    Issuance (Retirement) of Debt, Net 0 0
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -38.676 -141.947 -107.564 -72.51 -35.373
    Cash From Operating Activities -32.993 -116.309 -89.17 -58.452 -30.288
    Cash From Operating Activities 0.536 2.106 1.576 1.058 0.518
    Non-Cash Items 3.969 19.794 14.89 9.842 4.862
    Changes in Working Capital 1.178 3.738 1.928 3.158 -0.295
    Cash From Investing Activities 19.517 58.443 102.058 87.96 68.251
    Capital Expenditures -0.137 -6.526 -6.244 -6.075 -5.214
    Other Investing Cash Flow Items, Total 19.654 64.969 108.302 94.035 73.465
    Cash From Financing Activities 17.581 122.908 122.8 0.132 0.019
    Financing Cash Flow Items -7.988 -7.853
    Issuance (Retirement) of Stock, Net 17.581 130.896 130.653 0.132 0.019
    Foreign Exchange Effects -0.005 0.001 -0.007 -0.003 0.003
    Net Change in Cash 4.1 65.043 135.681 29.637 37.985
    Issuance (Retirement) of Debt, Net
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Satter Management Co., L.P. Private Equity 13.2922 7056024 0 2023-03-31 MED
    Bain Capital Life Sciences Investors, LLC Investment Advisor 9.2054 4886616 0 2023-03-31 LOW
    Adage Capital Management, L.P. Hedge Fund 6.6875 3549975 0 2023-03-31 LOW
    Redmile Group, LLC Investment Advisor/Hedge Fund 6.5993 3503190 0 2023-03-31 LOW
    VR Adviser, LLC Venture Capital 6.066 3220050 0 2023-03-31 MED
    Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 5.7603 3057800 0 2023-03-31 LOW
    Citadel Advisors LLC Hedge Fund 4.5459 2413117 -87190 2023-03-31 HIGH
    Eventide Asset Management, LLC Investment Advisor 3.5175 1867250 -1759258 2023-03-31 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.9575 1569971 21100 2023-03-31 LOW
    GMT Capital Corp. Hedge Fund 2.6537 1408697 1408697 2023-03-31 MED
    Millennium Management LLC Hedge Fund 2.5702 1364343 837812 2023-03-31 HIGH
    Cormorant Asset Management, LP Hedge Fund 2.3548 1250000 1250000 2023-03-31 LOW
    Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 2.3222 1232713 0 2023-03-31 LOW
    Octagon Capital Advisors LP Hedge Fund 2.2417 1190000 1190000 2023-03-31 MED
    Driehaus Capital Management, LLC Investment Advisor/Hedge Fund 2.0552 1090986 -200586 2023-03-31 MED
    Invus Public Equities Advisors, LLC Investment Advisor 1.9183 1018303 1018303 2023-03-31 LOW
    Polar Capital LLP Investment Advisor/Hedge Fund 1.8838 1000000 1000000 2023-03-31 LOW
    Soleus Capital Management, L.P. Hedge Fund 1.7244 915400 915400 2023-03-31 HIGH
    Novartis AG Corporation 1.7157 910747 -1196497 2021-12-31 LOW
    Clarus Ventures, LLC Venture Capital 1.7147 910211 0 2023-03-31

    Start a global, multi-asset portfolio with an award-winning platform

    Desktop

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    Annexon, Inc. Company profile

    About Annexon Inc

    Annexon, Inc. is a clinical-stage biopharmaceutical company that is developing a pipeline of therapies for patients with classical complement-mediated disorders of the body, brain and eye. The Company’s product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. Its product candidate, ANX007, is an antigen-binding fragment (Fab), formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. It is also developing ANX009, which is an investigational, subcutaneous formulation of a Fab designed for the treatment of systemic autoimmune diseases. It has completed Phase 1b safety and dose-ranging clinical trials for ANX005 and ANX007 in patients with Guillain-Barre Syndrome (GBS) and glaucoma respectively. It is also conducting clinical trials in multiple serious autoimmune, neurodegenerative and ophthalmic diseases.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Annexon Inc revenues was not reported. Net loss applicable to common stockholders increased 85% to $130.3M. Higher net loss reflects Research and development increase of 91% to $67.1M (expense), Compensation and personnel-related increase from $11.9M to $24.4M (expense), Compensation and personnel-related increase from $5.7M to $13.6M (expense).

    Industry: Biopharmaceuticals

    1400 Sierra Point Parkway
    Bldg C Suite 200
    BRISBANE
    CALIFORNIA 94005
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Benjamin Franklin’s face on a $100 bill

    USD forecast: DXY slides in risk-off market sentiment

    The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.

    16:10, 24 May 2023
    Oil wells pictured in an oil field, silhouetted against clouds

    Oil price forecast: Will WTI and Brent regain momentum in 2023?

    Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.

    11:38, 22 May 2023
    businessman using a mobile phone to check stock market data

    Weekly Roundup: Tech stocks lead the way

    US stocks push higher as risk appetite surges despite the uncertainty

    13:39, 19 May 2023
    Japanese yen currency

    USD/JPY continues to build higher towards 138

    USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher

    11:50, 17 May 2023
    Gold bars on a black background with a diagram

    Gold price predictions for next 5 years: Will gold continue rising?

    The yellow metal reached near record-highs, yet will it maintain the momentum and for how long?

    07:50, 17 May 2023
    Close-up of a $20 banknote and gold bullion

    Gold price forecast: Will gold surpass record highs?

    The US debt ceiling concerns and the banking crisis have been favourable for gold, yet is there more upside potential?

    12:52, 16 May 2023

    Top AI stocks: What companies are leading the AI revolution?

    Unravel key AI market leaders and their latest products, key AI industry trends and forecasts.

    14:55, 15 May 2023

    People also watch

    Oil - Crude

    69.89 Price
    -4.330% 1D Chg, %
    Long position overnight fee -0.0146%
    Short position overnight fee -0.0073%
    Overnight fee time 21:00 (UTC)
    Spread 0.03

    Gold

    1,958.55 Price
    +0.790% 1D Chg, %
    Long position overnight fee -0.0183%
    Short position overnight fee 0.0101%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    XRP/USD

    0.50 Price
    +1.840% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.00424

    BTC/USD

    27,687.30 Price
    +0.040% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 60.00

    Still looking for a broker you can trust?

    Join the 530.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading